Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Antithymocyte Globulin · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | ACTIVE_COMPARATOR | 2 umbilical cord units: Second cord blood unit modulated with ProHema |
| Group 2 | ACTIVE_COMPARATOR | 2 umbilical cord units: First cord blood unit modulated with ProHema |
| Name | Type | Description |
|---|---|---|
| Fludarabine | DRUG | 30mg/m2/day IV x 6 days |
| Melphalan | DRUG | 100 mg/m2/day IV x 1 day |
| Antithymocyte Globulin | DRUG | 1mg/kg/day x 4 days |
| Sirolimus | DRUG | GVHD Prophylaxis: Target range 3-12 ng/ml |
| Tacrolimus | DRUG | GVHD Prophylaxis: Target range 5-10 ng/ml |
Inclusion Criteria: * Patients with hematologic malignancies for whom allogeneic stem cell transplantation is deemed clinically appropriate * Patient must be ineligible for traditional myeloablative transplantation according to treating physician * Lack of 6/6 or 5/6 HLA-matched related, 8/8 HLA-ma...
Antithymocyte Globulin is being investigated for use in hematologic malignancies, specifically in the context of allogeneic stem cell transplantation. It is being studied as part of a therapy involving ProHema modulated umbilical cord blood units in subjects with these conditions.
Antithymocyte Globulin is being developed by Fate Therapeutics, Inc., a biopharmaceutical company traded under the ticker symbol FATE on the stock market.
Antithymocyte Globulin is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 1 trial has been completed.
Antithymocyte Globulin has one completed clinical trial, NCT00890500, titled 'Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.' This Phase 1 study enrolled 12 participants in the United States.
Antithymocyte Globulin is classified as a small molecule therapeutic. It is being studied in the oncology therapeutic area for the treatment of hematologic malignancies.
The clinical trial for Antithymocyte Globulin, NCT00890500, was not randomized and was not double-blind. It used an active control group, meaning participants received an alternative active treatment rather than a placebo.